| Trial name or title | A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer |
| Methods | Phase 3, multicentre, randomised, double‐blind, placebo‐controlled study |
| Participants | Platinum‐sensitive ovarian cancer patients who have either gBRCAmut or a tumour with high‐grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent |
| Interventions | 2:1 ratio of niraparib versus placebo Administered once daily continuously during a 28‐day cycle |
| Outcomes | Progression‐free survival overall survival Quality of life Safety and tolerability |
| Starting date | June 2013 |
| Contact information | Shefali Agarwal; Sagarwal@tesarobio.com |
| Notes | Estimated completion date October 2016. Last updated 23 Feb 2015. Last accessed 7 April 2015. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.